IRhythm Technologies Announces Japanese Regulatory Approval of the Zio ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
IRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
IRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio Monitor at HRX 2024 Meeting
Morgan Stanley Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $120
Morgan Stanley analyst Kallum Titchmarsh maintains $iRhythm Technologies(IRTC.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success
IRhythm Technologies Strikes Advanced Tech Licensing Deal
Express News | IRhythm : To Pay Biois Upfront Fee of $15.0 Million in Cash Upon Co's Acceptance of Initial Transfer of Certain Data Post Execution of Deal